-transparent.png){kind=logo}
We studied the neuroprotective effect of vigabatrin (gamma-vinyl GABA, VGB) in the rat hippocampus after status epilepticus (SE) induced by kainic acid (KA). Rats were treated with VGB (500 or 1000 mg/kg, i.p.) 24 h before KA injection (9 mg/kg, i.p.). The lower dose of VGB had no effect on the generation or severity of convulsions. However, VGB decreased neuronal damage in the CA3a (P < 0.05) and CA1 (P < 0.01) subfields of the hippocampus. The higher dose of VGB attenuated the severity of convulsions (P < 0.05) but had no effect on the development or generalization of convulsions. This finding may have clinical implications in the prevention of neuronal damage induced by drug refractory seizures or SE.
T Halonen, and
R Miettinen, and
A Toppinen, and
J Tuunanen, and
T Kotti, and
P J Riekkinen
December 1999,
Neuroscience letters,
T Halonen, and
R Miettinen, and
A Toppinen, and
J Tuunanen, and
T Kotti, and
P J Riekkinen
October 1999,
The European journal of neuroscience,
T Halonen, and
R Miettinen, and
A Toppinen, and
J Tuunanen, and
T Kotti, and
P J Riekkinen
April 1996,
Brain research,
T Halonen, and
R Miettinen, and
A Toppinen, and
J Tuunanen, and
T Kotti, and
P J Riekkinen
July 2016,
Neurotoxicology,
T Halonen, and
R Miettinen, and
A Toppinen, and
J Tuunanen, and
T Kotti, and
P J Riekkinen
November 2001,
Neuroscience letters,
T Halonen, and
R Miettinen, and
A Toppinen, and
J Tuunanen, and
T Kotti, and
P J Riekkinen
August 2021,
Cell biochemistry and function,
T Halonen, and
R Miettinen, and
A Toppinen, and
J Tuunanen, and
T Kotti, and
P J Riekkinen
January 2015,
Biological & pharmaceutical bulletin,
T Halonen, and
R Miettinen, and
A Toppinen, and
J Tuunanen, and
T Kotti, and
P J Riekkinen
December 2007,
Brain : a journal of neurology,
T Halonen, and
R Miettinen, and
A Toppinen, and
J Tuunanen, and
T Kotti, and
P J Riekkinen
June 2005,
Brain research,
T Halonen, and
R Miettinen, and
A Toppinen, and
J Tuunanen, and
T Kotti, and
P J Riekkinen
September 2007,
The Journal of pharmacology and experimental therapeutics,
